On March 2, 2023, the authors convened a group of experts from academia, industry, government, and nonprofits to explore technology options for increasing the resilience in the supply of generic prescription drugs. The workshop was convened at the Massachusetts Institute of Technology with the help of the National Network for Critical Technology Assessment and financial support from the Alfred P. Sloan Foundation. This report, authored by the organizers, summarizes the discussion. Because the workshop was not open to the public, this summary maintains the anonymity of the speakers and does not attribute comments to individuals.
Authors
- Acknowledgements and disclosures
- The authors would like to thank Rex Reklaitis, Joel Predd, Erika Fuchs, and Anita Kafka for their help with organizing the workshop.Wosinska and Conti's work in this area was supported by a grant from the National Science Foundation. Other than the aforementioned, the authors did not receive financial support from any firm or person for this article or from any firm or person with a financial or political interest in this article. The authors are not currently an officer, director, or board member of any organization with a financial or political interest in this article.The Brookings Institution is financed through the support of a diverse array of foundations, corporations, governments, individuals, as well as an endowment. A list of donors can be found in our annual reports published online here. The findings, interpretations, and conclusions in this report are solely those of its author(s) and are not influenced by any donation.
- Published in
- United States of America
